Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in Bioengineering and BiotechnologyOpen Access

From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJai Chand PatelMSMeenakshi ShuklaMSManish Shukla

Discussion

Loading...

Member takes

Overview

Recent advances in MSC therapies show promise for diseases like graft-versus-host disease and COVID-19, highlighting potential improvements in regenerative medicine.

Key Points

  • Mesenchymal stem cells have shown efficacy in treating conditions such as graft-versus-host disease and myocardial ischemia.
  • Clinical trials like REMODEL and REMEDY have demonstrated improved outcomes, supporting the clinical relevance of MSC-based therapies.
  • Innovative approaches, including CRISPR-modified MSCs and AI-driven platforms, aim to enhance the effectiveness and personalization of therapies.
  • Ongoing challenges in MSC therapies include variability, poor engraftment, and the need for robust regulatory frameworks.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790b6ehttps://doi.org/10.3389/fbioe.2025.1639439
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Next-generation approaches for mesenchymal stem cell characterization and therapeutic application2025 · 1 citations
  2. 2Advancing regenerative therapies with umbilical cord–derived mesenchymal stem cells: A review2025 · 6 citations
  3. 3Mesenchymal stromal cells: an update2025 · 4 citations
  4. 4The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics2025 · 18 citations
  5. 5The paracrine effect of mesenchymal cells: future perspectives2025 · 1 citations